Fenwick-Led Passage Bio Launches $126M IPO
Passage Bio Inc., an early-stage biotechnology firm developing therapies for central nervous system disorders, set a price range on Tuesday for an estimated $126 million initial public offering, guided by Fenwick...To view the full article, register now.
Already a subscriber? Click here to view full article